Search

Displaying results 2591 - 2600 of 5451 in total
  1. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated

  2. Drug

    Technetium Tc-99m tilmanocept

    go.drugbank.com/drugs/DB09266
    Approved

    It achieves high overall accuracy in detecting SLN [A32169]. … It is marketed under the trade name Lymphoseek. Potential application of technetium Tc-99m tilmanocept to other cancers are being investigated [A32170].

  3. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]

  4. Drug

    Nicardipine

    go.drugbank.com/drugs/DB00622
    ApprovedInvestigational

    It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem] … It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects.

    Products: CARDIBLOC-SR CAPSULE 40 mg, Nicardiin 1mg/ml Solution for Infusion
  5. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.

    Products: KANARB®PLUS FILM COATED TABLETS 60 MG/12.5 MG, KANARB®PLUS FILM COATED TABLETS 120 MG/12.5 MG
  6. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    It is currently discontinued.[L2368] … It is able to dissolve the intercellular matrix which helps with desquamation.

  7. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.

  8. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist. Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pi...

  9. Drug

    Tipranavir

    go.drugbank.com/drugs/DB00932
    ApprovedInvestigational

    Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.

  10. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    Aficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symp...